|
contact
|
|
EQUIPE 2 : PATHOGÉNIE ET COMMENSALISME DES ENTEROBACTÉRIES
TEAM 2 : PATHOGENESIS AND COMMENSALISM OF ENTEROBACTERIA |
Mini CV
- 2013 : Doctor in Veterinary Medicine (DVM)
- 2012 - 2013 : Master degree in cancerology at Paul Sabatier University, Toulouse
- 2013 - 2016 : PhD in cancerology at the Cancer Research Center of Toulouse.
- 2013 : Obtention du diplôme d’Etat de docteur en médecine vétérinaire, Ecole Nationale Vétérinaire de Toulouse.
- 2012 - 2013 : Master 2 Recherche Cancérologie (M2R), Université Paul Sabatier (UPS), Toulouse
- 2013 - 2016 : doctorat universitaire en cancérologie réalisé au Centre de Recherches en Cancérologie de Toulouse.
Recherche/projet research/project
Prevalence and persistence of pathogenic and antibiotic resistant bacteria
Prevalence et persistence des bactéries antibiorésistantes et pathogènes
Prevalence et persistence des bactéries antibiorésistantes et pathogènes
Production scientifique scientific production
L. David, F. Taieb , M. Pénary, PJ. Bordignon, R. Planès, V. Duplan-Eche, E. Meunier , E. Oswald. Outer membrane vesicles produced by pathogenic strains of Escherichia coli block autophagic flux and exacerbate inflammasome activation. Autophagy 2022. 1-13 doi: 10.1080/15548627.2022.2054040. Online ahead of print.
L. David, A. Fernandez-Vidal, S. Bertoli, S. Grgurevic, B. Lepage, D. Deshaies, N. Prade, M. Cartel, C. Larrue, J-E Sarry, E. Delabesse, C. Cazaux, C. Didier, C. Récher, S. Manenti, J-S. Hoffmann, CHK1 as a therapeutic target to bypass chemoresistance in AML, Science Signaling. 2016 Sep 13;9(445):ra90.
L. David, S. Manenti, C. Récher, J-S. Hoffmann, C. Didier, Targeting ATR/CHK1 pathway in Acute Myeloid Leukemia to overcome chemoresistance, Molecular & Cellular Oncology, 2017, VOL. 0, NO. 0
LL Yuan, A Green, L David, C Dozier, C Recher, C Didier, J Tamburini, S Manenti, Targeting CHK1 inhibits cell proliferation in FLT3-ITD positive acute myeloid leukemia, Leuk Res. 2014 Nov ;38(6) 1342-49
S. Bertoli, H. Boutzen, L. David, C. Larrue, F. Vergez, A. Fernandez-Vidal, LL. Yuan, M-a. Hospital, J. Tamburini, C. Demur, E. Delabesse, E. Saland, J-E Sarry, M-O. Galcera, V. Mansat-De Mas, C. Didier, C. Dozier, C. Récher, S. Manenti, CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia, Oncotarget. 2015 Nov 10; 6(35) 38061–38078.
L. David, A. Fernandez-Vidal, S. Bertoli, S. Grgurevic, B. Lepage, D. Deshaies, N. Prade, M. Cartel, C. Larrue, J-E Sarry, E. Delabesse, C. Cazaux, C. Didier, C. Récher, S. Manenti, J-S. Hoffmann, CHK1 as a therapeutic target to bypass chemoresistance in AML, Science Signaling. 2016 Sep 13;9(445):ra90.
L. David, S. Manenti, C. Récher, J-S. Hoffmann, C. Didier, Targeting ATR/CHK1 pathway in Acute Myeloid Leukemia to overcome chemoresistance, Molecular & Cellular Oncology, 2017, VOL. 0, NO. 0
LL Yuan, A Green, L David, C Dozier, C Recher, C Didier, J Tamburini, S Manenti, Targeting CHK1 inhibits cell proliferation in FLT3-ITD positive acute myeloid leukemia, Leuk Res. 2014 Nov ;38(6) 1342-49
S. Bertoli, H. Boutzen, L. David, C. Larrue, F. Vergez, A. Fernandez-Vidal, LL. Yuan, M-a. Hospital, J. Tamburini, C. Demur, E. Delabesse, E. Saland, J-E Sarry, M-O. Galcera, V. Mansat-De Mas, C. Didier, C. Dozier, C. Récher, S. Manenti, CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia, Oncotarget. 2015 Nov 10; 6(35) 38061–38078.
